<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0011663'>Arrhythmogenic right ventricular cardiomyopathy</z:hpo> (ARVC) is a rare genetically transmitted disease prone to <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore investigated the clinical, echocardiographical and electrophysiological predictors of appropriate implantable cardioverter defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy in patients with ARVC </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A retrospective analysis was performed in 26 patients (median age of 40 years at diagnosis, 21 males and 5 females) with ARVC who underwent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Over a median (range) follow-up period of 10 (2.7, 37) years, appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy for <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> was documented in 12 (46%) out of 26 patients </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients with appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> was originally inserted for secondary prevention </plain></SENT>
<SENT sid="5" pm="."><plain>Median time from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy was 9 months (range 3.6, 54 months) </plain></SENT>
<SENT sid="6" pm="."><plain>History of <z:hpo ids='HP_0001635'>heart failure</z:hpo> was a significant predictor of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy (p = 0.033) </plain></SENT>
<SENT sid="7" pm="."><plain>Left ventricular disease involvement (p = 0.059) and age at implantation (p = 0.063) were borderline significant predictors </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:hpo ids='HP_0001279'>syncope</z:hpo> at time of diagnosis were significantly less likely to receive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy (p = 0.02) </plain></SENT>
<SENT sid="9" pm="."><plain>Invasive electrophysiological testing was not significantly associated with appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: In our cohort of patients with ARVC, history of <z:hpo ids='HP_0001635'>heart failure</z:hpo> was a significant predictor of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy, whereas left ventricular involvement and age at time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation were of borderline significance </plain></SENT>
<SENT sid="11" pm="."><plain>These predictors should be tested in larger prospective cohorts to optimize <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in this rare <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>